We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.14%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.52B
AUM Growth
+$385M
Cap. Flow
+$3.2M
Cap. Flow %
0.04%
Top 10 Hldgs %
34.42%
Holding
155
New
17
Increased
44
Reduced
30
Closed
23

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$102M
2
CFN
CAREFUSION CORPORATION
CFN
+$68.7M
3
BMY icon
Bristol-Myers Squibb
BMY
+$60.2M
4
SHPG
Shire pic
SHPG
+$55.3M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$54M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$146M
2
AGN
Allergan Inc
AGN
+$113M
3
PRTA icon
Prothena Corp
PRTA
+$72.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$63M
5
XLRN
Acceleron Pharma
XLRN
+$56.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.59%
2 Financials 0.08%
3 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
126
CALL
DELISTED
Zogenix, Inc.
ZGNX
$417K ﹤0.01%
25,950
-12,500
-33% -$226K
ABBV icon
127
CALL
AbbVie
ABBV
$471B
– –
-250,000
Closed -$12.8M
AZN icon
128
CALL
AstraZeneca
AZN
$271B
– –
-200,000
Closed -$13M
BLUE
129
DELISTED
bluebird bio
BLUE
– –
-22,311
Closed -$6.57M
BMY icon
130
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-750,000
Closed -$39M
EXAS
131
PUT
DELISTED
Exact Sciences
EXAS
– –
-100,000
Closed -$1.42M
EXEL icon
132
Exelixis
EXEL
$14B
– –
-2,888,000
Closed -$10.2M
GILD icon
133
PUT
Gilead Sciences
GILD
$166B
– –
-75,000
Closed -$5.32M
INO icon
134
Inovio Pharmaceuticals
INO
$83.1M
– –
-83,063
Closed -$13.3M
MGNX icon
135
MacroGenics
MGNX
$234M
– –
-491,897
Closed -$13.7M
MNKD icon
136
PUT
MannKind Corp
MNKD
$1.21B
– –
-80,000
Closed -$1.61M
PRGO icon
137
CALL
Perrigo
PRGO
$1.45B
– –
-50,000
Closed -$7.73M
PRTA icon
138
Prothena Corp
PRTA
$442M
– –
-1,889,000
Closed -$72.4M
UNH icon
139
UnitedHealth
UNH
$387B
– –
-102,000
Closed -$8.36M
VRTX icon
140
PUT
Vertex Pharmaceuticals
VRTX
$124B
– –
-97,100
Closed -$6.87M
ATRS
141
DELISTED
Antares Pharma, Inc.
ATRS
– –
-3,213,900
Closed -$11.2M
GWPH
142
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-95,500
Closed -$5.67M
TSRO
143
DELISTED
TESARO, Inc.
TSRO
– –
-847,800
Closed -$25M
AEGR
144
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-200,000
Closed -$9.24M
AEGR
145
PUT
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-200,000
Closed -$9.24M
QLTI
146
DELISTED
QLT Inc
QLTI
– –
-300,000
Closed -$1.67M
CFN
147
CALL
DELISTED
CAREFUSION CORPORATION
CFN
– –
-250,000
Closed -$10.1M
CVD
148
DELISTED
COVANCE INC.
CVD
– –
-63,000
Closed -$6.55M
RPTP
149
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-600,000
Closed -$6M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2014 Portfolio in Review

As of Q2 2014, OrbiMed held 155 positions worth $8.52B, up 4.7% from $8.13B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2014 filing shows 17 new, 44 increased, 30 reduced and 23 closed positions. Its largest new stake was Alkermes: 433,300 shares worth $21.8M. The largest sale was Gilead Sciences, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2014 buy was Alkermes: 433,300 shares worth $21.8M.
  • OrbiMed added most to Ironwood Pharmaceuticals in Q2 2014, an estimated $102M increase.
  • OrbiMed's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $146M.
  • OrbiMed fully exited Prothena Corp in Q2 2014, selling an estimated $72.4M.
  • OrbiMed's ten largest holdings make up 34% of its $8.52B portfolio in Q2 2014.
  • OrbiMed opened 17 new positions and closed 23 in Q2 2014.
  • OrbiMed's portfolio value rose 4.7% quarter-over-quarter to $8.52B.

Based on OrbiMed's 13F filing for Q2 2014, filed 14 Aug 2014.